ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker - 04/04/19
pages | 10 |
Iconographies | 4 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | APP cleavage by the α-secretase ADAM10 releases the soluble portion sAβPPα and prevents the generation of senile plaques. |
• | Non-amyloidogenic pathway remains largely unknown and ignored, mainly regarding natural compounds effects on ADAM10. |
• | This review emphasizes the effects of natural compounds on ADAM10 modulation as a neuroprotective mechanism against AD. |
• | New treatments and preventive interventions targeting ADAM10 regulation for AD are necessary. |
Abstract |
Alzheimer’s disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-β (Aβ) peptides are formed by amyloid-β precursor protein (AβPP) cleavage, which can be processed by two pathways. The cleavage by the α-secretase A Disintegrin And Metalloprotease 10 (ADAM10) releases the soluble portion (sAβPPα) and prevents senile plaques. This pathway remains largely unknown and ignored, mainly regarding pharmacological approaches that may act via different signaling cascades and thus stimulate non-amyloidogenic cleavage through ADAM10. This review emphasizes the effects of natural compounds on ADAM10 modulation, which eventuates in a neuroprotective mechanism. Moreover, ADAM10 as an AD biomarker is revised. New treatments and preventive interventions targeting ADAM10 regulation for AD are necessary, considering the wide variety of ADAM10 substrates.
Le texte complet de cet article est disponible en PDF.Keywords : Alzheimer’s disease, ADAM10, Pharmaceutical, Natural compounds, α-Secretase
Plan
Vol 113
Article 108661- mai 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?